NCT03312842: A Phase Ia/Ib Study of CS1001 in Advanced Solid Tumors

NCT03312842
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known brain metastasis or other CNS metastasis that is either symptomatic or untreated
https://ClinicalTrials.gov/show/NCT03312842

Comments are closed.

Up ↑